Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Pre-Close Trading Update

12 May 2022 07:00

RNS Number : 1871L
Ideagen PLC
12 May 2022
 

12 May 2022

Ideagen PLC

("Ideagen," "the Company" or the "Group'')

 

Pre-Close Trading Update

Organic growth ahead of market expectations; continued execution of M&A strategy

Ideagen PLC (AIM: IDEA), a leader in compliance software for regulated industries, is pleased to provide an update on trading for the year ended 30 April 2022.

Trading Update

The Board is pleased to report a year of continued organic growth augmented by strategic acquisitions. Underpinning this momentum is the growing need for assurance, compliance, and collaboration services across sectors served by Ideagen such as healthcare and financial services.

 

For the year ended 30 April 2022, the Group expects to report total revenue up 41% at approximately £92.2m (FY 2021: £65.6m) and adjusted EBITDA1 up 33% to approximately £30.5m (FY 2021: £22.9m) (see footnote titled Profit Estimate).

 

The Company demonstrated strong growth in its high-quality recurring revenues. Annual Recurring Revenue2 ("ARR") recognised during the financial year is expected to be £78.9m (FY 2021: £54.2m), representing 86% of total revenues, up from 83% in the comparative prior period.

 

The ARR book of contracted revenue to be recognised over the coming 12 months increased by 48% during the financial year to approximately £96.3m (FY 2021: £65.2m2), reflecting strong organic growth of approximately 14% in addition to acquisitions. Ideagen's growth was supported by continued strong customer retention rates as well as new business wins.

 

Cash generated by operations during the financial year is expected to be more than 100% of adjusted EBITDA resulting in a net bank debt balance at 30 April 2022 of £2.1m with a total Revolving Credit Facility of £100m.

 

The Group continues to focus on organic growth as well as the seamless integration of newly acquired businesses. The Board remains confident in the Company's outlook based upon the structural drivers in the sector, as well as the continued execution of the stated strategy.

 

On 9 May 2022, the Board of Ideagen reached agreement on the terms of a recommended cash acquisition by Hg, a leading software and services investor, for the entire issued and to be issued share capital of Ideagen. Ideagen's Directors intend to recommend unanimously that Ideagen shareholders vote in favour of the acquisition at the forthcoming shareholder meetings (or, in the event that the acquisition is implemented by way of a takeover offer, that they accept or procure acceptance of the offer). It is anticipated that the acquisition will complete in July 2022, subject to satisfaction or (where applicable) waiver of conditions laid out in the announcement on 9 May 2022. The Board remains in discussions with Astorg, who have been granted access to due diligence. There can be no certainty that a firm offer will be made by Astorg, nor as to the terms of any such offer.

 

The Group expects to announce its preliminary full year results on or around 5 July 2022.

 

Ben Dorks, Chief Executive Officer of Ideagen, said:

 

"I am pleased to report another strong year for Ideagen, delivering strong organic growth and customer momentum. We have completed seven acquisitions that significantly extend our leadership in compliance software for regulated industries and expect to derive synergy opportunities once integrated. Our primary focus remains growing our recurring revenues and expanding our customer base. The offer received from Hg reflects the quality, track record and future growth potential of Ideagen. Given the momentum in the Group, we remain confident about the year ahead."

 

Enquiries:

Ideagen plc

01629 699 100

Ben Dorks, Chief Executive Officer

Emma Hayes, Chief Financial Officer

 

Canaccord Genuity Limited (Nomad)

020 7523 8000

Simon Bridges

Georgina McCooke

 

 

 

Numis Securities Limited

020 7260 1000

Simon Willis

Joshua Hughes

 

 

 

 

 

FTI Consulting

020 3727 1000

Jamie Ricketts

ideagen@fticonsulting.com

Dwight Burden

Valerija Cymbal

 

About Ideagen plc

Ideagen's software helps companies comply with regulation and manage risk.

Ideagen is a leader in the +$30 billion regulatory and compliance software market, serving highly regulated industries such as life sciences, healthcare, banking and finance and insurance. 

More than 8,000 customers use Ideagen's software, including leading accounting and pharmaceutical firms.

Ideagen has a track record of 12 years of profitable growth and strong cash generation with high levels of recurring revenues (representing an expected 86% of total revenues for the year ended 30 April 2022).

Ideagen has a diversified customer base including blue chip, global brands such as Heineken, British Airways, Aggreko, Bank of New York and Johnson Matthey.

Ideagen is headquartered in the UK, listed on the London Stock Exchange AIM market (Ticker: IDEA.L), and has key hubs in the UK, USA, Middle East and South East Asia. For further information please visit www.ideagen.com.

 

Profit Estimate

The statement above that includes that Adjusted EBITDA1 for the year ended 30 April 2022 is expected to be £30.5 million constitutes a profit estimate for the purposes of Rule 28.1 of the City Code of Takeovers and Mergers (the "Profit Estimate").

Ideagen Directors confirmation and basis of preparation.

The principal assumption upon which the Profit Estimate has been compiled is that no changes are required to be made as a result of 2022 financial year end accounting close or related external audit procedures.

The Ideagen Directors confirm that the Profit Estimate remains valid and has been properly compiled on the basis of the assumption stated above, and that the basis of accounting used is consistent with Ideagen's accounting policies, which are in accordance with IFRS and those that Ideagen applied in the preparation of its financial statements for the year ended 30 April 2021 and will apply in preparing its financial statements for the financial year ended 30 April 2022.

 

Notes

1Earnings before interest, tax, depreciation and amortisation adjusted for transaction costs, restructuring costs, finance costs and share-based payments.

2ARR comprises contracted revenue that will be recognised over the coming 12 months. The growth figures are calculated using an opening ARR that has been adjusted for constant currency exchange rates and to remove the revenues related to the in-period divestment.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBCGDUXGBDGDB
Date   Source Headline
12th Nov 20207:00 amRNSPre-Close Trading Update and Board Changes
5th Nov 202010:46 amRNSPDMR Shareholding and Exercise of Options
4th Nov 20202:30 pmRNSHolding(s) in Company
29th Oct 202011:28 amRNSHolding(s) in Company
28th Oct 20203:59 pmRNSResult of AGM
21st Oct 20202:59 pmRNSHolding(s) in Company
16th Oct 202012:44 pmRNSExercise of share options and Total Voting Rights
14th Oct 20207:00 amRNSIssue of Equity and Total Voting Rights
5th Oct 20202:19 pmRNSNotice of AGM
2nd Oct 20201:52 pmRNSHolding(s) in Company
1st Oct 20208:28 amRNSPDMR Dealing and Exercise of Options
29th Sep 20205:51 pmRNSIssue of New Shares
22nd Sep 20207:00 amRNSFinal Results
15th Sep 20203:10 pmRNSHolding(s) in Company
24th Aug 20202:36 pmRNSHolding(s) in Company
19th Aug 20203:55 pmRNSIssue of New Shares
10th Aug 20207:00 amRNSTrading Update and Acquisition of Qualsys Ltd
14th Jul 20208:44 amRNSExercise of Options and TVR
1st Jul 20207:00 amRNSBoard Changes
24th Jun 20204:41 pmRNSSecond Price Monitoring Extn
24th Jun 20204:36 pmRNSPrice Monitoring Extension
22nd Jun 20207:00 amRNSExercise of Options and Total Voting Rights
16th Jun 20207:00 amRNSExercise of Options and TVR
26th May 20208:30 amRNSExercise of Options and TVR
22nd May 20207:00 amRNSPartnership with the World Health Organisation
21st May 20201:06 pmRNSHolding(s) in Company
19th May 20207:00 amRNSPre-Close Trading Update
28th Apr 20202:26 pmRNSExercise of Options and TVR
22nd Apr 20207:00 amRNSIssue of New Shares, Director Dealings and TVR
9th Apr 20207:00 amRNSExercise of Options and TVR
7th Apr 20207:00 amRNSCOVID-19 Trading Update
30th Mar 20207:00 amRNSIssue of new shares under SIP and TVR
6th Mar 20207:00 amRNSAcquisition of Workrite Ltd
25th Feb 202011:09 amRNSIssue of Equity
27th Jan 20204:56 pmRNSExercise of Options and TVR
22nd Jan 20207:00 amRNSInterim Results
20th Jan 20205:10 pmRNSIssue of Equity under Share Incentive Plan
7th Jan 20207:00 amRNSBoard Change
17th Dec 20194:08 pmRNSIssue of Equity
13th Dec 20194:38 pmRNSDirector/PDMR Shareholding
3rd Dec 20192:44 pmRNSHolding(s) in Company
2nd Dec 201911:29 amRNSPDMR Dealing and Total Voting Rights
29th Nov 20199:57 amRNSHolding(s) in Company
21st Nov 20194:06 pmRNSHolding(s) in Company
20th Nov 201911:58 amRNSDirector/PDMR Dealings and Total Voting Rights
18th Nov 20192:00 pmRNSIssue of Shares under Share Incentive Plan
13th Nov 20197:00 amRNSTrading Update
30th Oct 20193:48 pmRNSResult of AGM
24th Oct 20197:00 amRNSBoard Change
23rd Oct 201911:45 amRNSShare Incentive Plan and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.